
Opinion|Videos|June 9, 2025
Translating the Trial: How Findings from ARANOTE May Inform Treatment Decisions
Author(s)Quoc-Dien Trinh, MD, MPH
Research highlights the effectiveness and safety of mHSPC treatments for black men, ensuring they receive appropriate care and reassurance.
Advertisement
Episodes in this series

Clinical Implications for Patient Care
Key Themes:
- Study findings directly inform the treatment of Black men with prostate cancer.
- Results confirm drug efficacy in this specific population.
- Data support equal eligibility of Black men for darolutamide treatment.
- Findings provide reassurance regarding a comparable benefit-risk profile.
Key Points for Physicians:
- Confidently recommend darolutamide to eligible Black patients.
- Use these data to address potential concerns about efficacy in diverse populations.
- Reassure patients regarding a comparable benefit-risk profile across racial groups.
Notable Insights: These findings provide clinicians with specific, evidence-based information to address potential concerns from clinicians and patients about treatment efficacy in Black men.
Clinical Significance: The confirmed efficacy and safety in Black men support equitable treatment recommendation practices and may help reduce disparities in advanced therapeutic approaches.
Advertisement
Related to this article

Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.

An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.

This FAQ outlines key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.

Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.

The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.

Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
Avoiding False Positives on Prostate Cancer PSMA PET Scans
2
2026 AUA/SUO NMIBC guideline: Key updates for clinical practice
3
Decipher may help identify ADT benefit in intermediate-risk prostate cancer
4
AUA South Central Section Meeting: Mark D. Tyson, II, MD, MPH, recaps data in NMIBC
5


